Investing.com - Crispr Therapeutics (NASDAQ: CRSP) reported first quarter EPS of $-1.58, $0.37 worse than the analyst estimate of $-1.21. Revenue for the quarter came in at $860K versus the consensus estimate of $7.1M.
Crispr Therapeutics’s stock price closed at $33.14. It is down -16.54% in the last 3 months and down -40.32% in the last 12 months.
Crispr Therapeutics saw 6 positive EPS revisions and 2 negative EPS revisions in the last 90 days. See Crispr Therapeutics’s stock price’s past reactions to earnings here.
According to InvestingPro, Crispr Therapeutics’s Financial Health score is "fair performance".
Check out Crispr Therapeutics’s recent earnings performance, and Crispr Therapeutics’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar
Most traders can read a chart. The hard part is the moment: entry window open, pattern forming, and you're still waiting for more confirmation. That's the conviction gap — and our chart analysis closes it. Unlike other AIs that just read data, our Vision AI literally "sees" your charts and hands you a complete trading plan: entry, stop-loss, and profit target in under 60 seconds. Know exactly what to do next, every time.